• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca PLC - American Depositary Shares (NY:AZN)

    165.67 -0.91 (-0.55%)
    Streaming Delayed Price Updated: 11:31 AM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about AstraZeneca PLC - American Depositary Shares

    < Previous 1 2 Next >
    News headline image
    Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
    From AstraZeneca
    Via Business Wire
    News headline image
    ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
    From AstraZeneca
    Via Business Wire
    News headline image
    A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
    A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
    From MarketNewsUpdates.com
    Via GlobeNewswire
    News headline image
    Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
    News Provided by USA News Group on behalf of MindWalk Holdings Corp. 
    From USA News Group
    Via GlobeNewswire
    News headline image
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
    From AstraZeneca
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca results: H1 and Q2 2026
    From AstraZeneca
    Via Business Wire
    News headline image
    AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
    From AstraZeneca
    Via Business Wire
    BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
    Via Investor Brand Network
    News headline image
    TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
    From AstraZeneca
    Via Business Wire
    News headline image
    IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
    From AstraZeneca
    Via Business Wire
    News headline image
    DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
    From AstraZeneca
    Via Business Wire
    News headline image
    AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
    From AstraZeneca
    Via Business Wire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.